Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
Pipeline News and Updates
Picture

Update for March 23, 2023

3/23/2023

 
Regulatory Update
 
The FDA accepted the resubmitted NDA for palovarotene after Ipsen provided the additional clinical data that was requested. A PDUFA date was set for 8/16/2023.
 
The FDA rejected the combination of foscarbidopa and foslevodopa for the treatment of motor fluctuations in patients with advanced Parkinson's disease and requested additional information about the pump used to administer the drugs.

Tofersen
  • An FDA review of tofersen found that while tofersen did not improve the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale in the Phase III, VALOR trial, the levels of SOD1 protein in cerebrospinal fluid and neurofilament light chain (NfL) in plasma did decrease. NfL has been shown to be significantly elevated in patients with ALS and prognostic for disease progression. SOD1 protein, is a proven contributor to the pathophysiology of SOD1-ALS.
  • The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee (PCNSDAC) voted 9 to 0 that that biomarker evidence supports conditional approval for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). The PCHSDAC felt it was reasonably likely that a decrease in plasma neurofilament light chain concentrations would predict clinical benefit of tofersen for treatment of patients with SOD1-ALS. However, the PCHSDAC voted 5 to 3 against recommending full approval due to limitations in the VALOR trial. The PDUFA date for tofersen is 4/25/2023.
  • Biogen is continuing to evaluate tofersen as a treatment for SOD1-ALS in the ongoing open label extension of the VALOR trial and the 12-month, 150 patient, Phase III ATLAS trial (NCT04856982) in patients who have not developed symptomatic ALS but are at increased risk due to a SOD1 mutation and biomarker evidence of disease activity.

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    May 2023
    April 2023
    March 2023
    February 2023
    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.